UA76463C2 - Pharmaceutical dosage form of amorphous nelfinavir mesylate - Google Patents
Pharmaceutical dosage form of amorphous nelfinavir mesylate Download PDFInfo
- Publication number
- UA76463C2 UA76463C2 UA20031210981A UA20031210981A UA76463C2 UA 76463 C2 UA76463 C2 UA 76463C2 UA 20031210981 A UA20031210981 A UA 20031210981A UA 20031210981 A UA20031210981 A UA 20031210981A UA 76463 C2 UA76463 C2 UA 76463C2
- Authority
- UA
- Ukraine
- Prior art keywords
- nelfinavir mesylate
- dosage form
- form according
- copolymer
- nelfinavir
- Prior art date
Links
- 229960005230 nelfinavir mesylate Drugs 0.000 title claims abstract description 77
- NQHXCOAXSHGTIA-SKXNDZRYSA-N nelfinavir mesylate Chemical compound CS(O)(=O)=O.CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 NQHXCOAXSHGTIA-SKXNDZRYSA-N 0.000 title claims abstract description 77
- 239000002552 dosage form Substances 0.000 title claims abstract description 16
- 229920001577 copolymer Polymers 0.000 claims abstract description 21
- 239000007787 solid Substances 0.000 claims abstract description 20
- 229920001400 block copolymer Polymers 0.000 claims abstract description 19
- 238000002844 melting Methods 0.000 claims abstract description 18
- 230000008018 melting Effects 0.000 claims abstract description 18
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims abstract description 11
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000003826 tablet Substances 0.000 claims description 54
- 239000000203 mixture Substances 0.000 claims description 36
- 239000008187 granular material Substances 0.000 claims description 20
- 239000000155 melt Substances 0.000 claims description 12
- 239000012458 free base Substances 0.000 claims description 10
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 claims description 9
- 229960000884 nelfinavir Drugs 0.000 claims description 9
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 6
- 238000012545 processing Methods 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 5
- 239000000945 filler Substances 0.000 claims description 5
- 238000000354 decomposition reaction Methods 0.000 claims description 4
- 239000007884 disintegrant Substances 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- 239000000080 wetting agent Substances 0.000 claims description 3
- 239000007894 caplet Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 101800001776 Nuclear inclusion protein B Proteins 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 13
- 238000007909 melt granulation Methods 0.000 abstract description 9
- 239000012943 hotmelt Substances 0.000 abstract description 5
- 238000004090 dissolution Methods 0.000 description 18
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
- 229940079593 drug Drugs 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 235000019359 magnesium stearate Nutrition 0.000 description 7
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 6
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 239000006186 oral dosage form Substances 0.000 description 5
- 229920001983 poloxamer Polymers 0.000 description 5
- 229920002261 Corn starch Polymers 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 239000008190 ground granulate Substances 0.000 description 4
- 229940126601 medicinal product Drugs 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 238000005550 wet granulation Methods 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 239000000378 calcium silicate Substances 0.000 description 3
- 229910052918 calcium silicate Inorganic materials 0.000 description 3
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 229960000913 crospovidone Drugs 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000001087 glyceryl triacetate Substances 0.000 description 3
- 235000013773 glyceryl triacetate Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 229940124531 pharmaceutical excipient Drugs 0.000 description 3
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 3
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 229960002622 triacetin Drugs 0.000 description 3
- ZHXUEUKVDMWSKV-UHFFFAOYSA-N 1-(3,5-ditert-butyl-4-hydroxyphenyl)hex-5-yn-1-one Chemical compound CC(C)(C)C1=CC(C(=O)CCCC#C)=CC(C(C)(C)C)=C1O ZHXUEUKVDMWSKV-UHFFFAOYSA-N 0.000 description 2
- 229920005682 EO-PO block copolymer Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- 239000006255 coating slurry Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000007888 film coating Substances 0.000 description 2
- 238000009501 film coating Methods 0.000 description 2
- 239000011874 heated mixture Substances 0.000 description 2
- 238000004859 neutralization-reionization mass spectrometry Methods 0.000 description 2
- 239000008023 pharmaceutical filler Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229960000502 poloxamer Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- -1 polyoxyethylene Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 229950003441 tebufelone Drugs 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 101100187130 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) nim-1 gene Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000004174 erythrosine Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28841001P | 2001-05-03 | 2001-05-03 | |
| PCT/EP2002/004711 WO2002089835A2 (en) | 2001-05-03 | 2002-04-29 | Pharmaceutical dosage form of amorphous nelfinavir mesylate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA76463C2 true UA76463C2 (en) | 2006-08-15 |
Family
ID=23106974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA20031210981A UA76463C2 (en) | 2001-05-03 | 2002-04-29 | Pharmaceutical dosage form of amorphous nelfinavir mesylate |
Country Status (37)
| Country | Link |
|---|---|
| US (1) | US7014866B2 (de) |
| EP (1) | EP1390063B1 (de) |
| JP (1) | JP4101661B2 (de) |
| KR (1) | KR100554816B1 (de) |
| CN (1) | CN1255185C (de) |
| AR (1) | AR034320A1 (de) |
| AT (1) | ATE282428T1 (de) |
| BG (1) | BG108311A (de) |
| BR (1) | BR0209325A (de) |
| CA (1) | CA2444116C (de) |
| CZ (1) | CZ20033211A3 (de) |
| DE (1) | DE60201988T2 (de) |
| EA (1) | EA006627B1 (de) |
| EC (1) | ECSP034827A (de) |
| ES (1) | ES2231717T3 (de) |
| GE (1) | GEP20053466B (de) |
| GT (1) | GT200200079A (de) |
| HK (1) | HK1070285A1 (de) |
| HR (1) | HRP20030873B1 (de) |
| HU (1) | HU229938B1 (de) |
| IL (2) | IL158306A0 (de) |
| IS (1) | IS7010A (de) |
| JO (1) | JO2401B1 (de) |
| MA (1) | MA27018A1 (de) |
| MX (1) | MXPA03009971A (de) |
| MY (1) | MY128509A (de) |
| NO (1) | NO20034689D0 (de) |
| NZ (1) | NZ528689A (de) |
| PA (1) | PA8544501A1 (de) |
| PE (1) | PE20021159A1 (de) |
| PL (1) | PL366998A1 (de) |
| PT (1) | PT1390063E (de) |
| RS (1) | RS83503A (de) |
| SK (1) | SK14572003A3 (de) |
| TW (1) | TWI234461B (de) |
| UA (1) | UA76463C2 (de) |
| WO (1) | WO2002089835A2 (de) |
Families Citing this family (112)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5767429B2 (ja) | 1999-11-12 | 2015-08-19 | アッヴィ・インコーポレイテッド | 固体分散剤中の結晶化阻害剤 |
| DE10026698A1 (de) | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
| CA2398226A1 (en) * | 2002-01-28 | 2003-07-28 | Pfizer Inc. | Increased-dosage nelfinavir tablet and method of making same |
| JP4731320B2 (ja) * | 2003-07-15 | 2011-07-20 | アリジェン製薬株式会社 | 抗コロナウイルス剤 |
| US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
| US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
| WO2005065657A2 (en) * | 2003-12-31 | 2005-07-21 | Pfizer Products Inc. | Solid compositions of low-solubility drugs and poloxamers |
| EP1904067B2 (de) * | 2004-12-03 | 2017-10-11 | Merck Sharp & Dohme Corp. | Pharmazeutische formulierung von carbonsäureamid-hiv-integraseinhibitoren mit einer zusammensetzung zur steuerung der abgabenrate |
| DK1928427T3 (da) * | 2005-09-23 | 2010-03-08 | Hoffmann La Roche | Hidtil ukendt dosisformulering |
| ES2350497T3 (es) * | 2005-12-14 | 2011-01-24 | F. Hoffmann-La Roche Ag | Formulación de profármacos para el vhc. |
| PL1962808T3 (pl) * | 2005-12-14 | 2011-03-31 | Hoffmann La Roche | Preparat proleku przeciw HCV |
| UY30535A1 (es) * | 2006-08-10 | 2008-03-31 | Cipla Ltd | Composicion comprendiendo farmacos antirretrovirales y al menos un polimero insoluble en agua, proceso de preparacion y aplicaciones. |
| CA2660086C (en) * | 2006-08-16 | 2014-09-16 | Novartis Ag | Method of making solid dispersions of highly crystalline therapeutic compounds |
| WO2008067164A2 (en) * | 2006-11-15 | 2008-06-05 | Abbott Laboratories | Solid pharmaceutical dosage formulations |
| US8759383B2 (en) | 2007-03-16 | 2014-06-24 | Concert Pharmaceuticals, Inc. | Inhibitors of cholesterol ester transfer protein |
| WO2008131259A1 (en) * | 2007-04-19 | 2008-10-30 | Concert Pharmaceuticals Inc. | Deuterated morpholinyl compounds |
| US20090042842A1 (en) | 2007-04-25 | 2009-02-12 | Concert Pharmaceuticals, Inc. | Analogues of cilostazol |
| CA2630084A1 (en) * | 2007-04-30 | 2008-10-30 | Mark Andreychuk | Coiled tubing with retainer for conduit |
| US9194512B2 (en) | 2007-04-30 | 2015-11-24 | Mark Andreychuk | Coiled tubing with heat resistant conduit |
| US7608737B2 (en) | 2007-05-01 | 2009-10-27 | Concert Pharmaceuticasl Inc. | Naphthyl(ethyl)acetamides |
| EP3632916B1 (de) | 2007-05-01 | 2022-06-08 | Concert Pharmaceuticals Inc. | Morphinanverbindungen |
| EP3825306B8 (de) | 2007-05-01 | 2023-08-02 | Sun Pharmaceutical Industries, Inc. | Morphinanverbindungen |
| PL2345653T3 (pl) | 2007-05-01 | 2013-05-31 | Concert Pharmaceuticals Inc | Związki morfianu |
| BRPI0823520A2 (pt) | 2007-06-12 | 2013-12-17 | Concert Pharmaceuticals Inc | Composto derivado de azapeptídeos e composição farmacêutica contendo o mesmo |
| US8410124B2 (en) * | 2007-10-18 | 2013-04-02 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
| BRPI0816513A2 (pt) * | 2007-10-19 | 2015-03-24 | Purdue Research Foundation | Composição farmacêutica e método para preparar a suspensão sólida |
| ITMI20080227A1 (it) * | 2008-02-13 | 2009-08-14 | Felice Vinati | '' dispositivo di sicurezza per apparati di sollevamento a fune '' |
| US20090239886A1 (en) | 2008-02-29 | 2009-09-24 | Concert Pharmaceuticals, Inc. | Substituted xanthine derivatives |
| WO2009146310A1 (en) * | 2008-05-28 | 2009-12-03 | Concert Pharmaceuticals Inc. | Deuterated tizanidine |
| WO2010019557A1 (en) * | 2008-08-12 | 2010-02-18 | Concert Pharmaceuticals Inc. | N-phenyl-2-pyrimidineamine derivatives |
| SI2334678T1 (sl) | 2008-09-19 | 2013-05-31 | Concert Pharmaceuticals Inc. | Spojine morfinana |
| EP2364151A1 (de) | 2008-10-30 | 2011-09-14 | Concert Pharmaceuticals Inc. | Kombination von morphinan-verbindungen und antidepressiva zur behandlung von pseudobulbärem affekt, neurologischen erkrankungen, hartnäckigen und chronischen schmerzen und gehirnverletzungen |
| EP3090760A1 (de) | 2008-10-30 | 2016-11-09 | Concert Pharmaceuticals, Inc. | Kombination von morphinanverbindungen und antidepressivum zur behandlung von pseudobulbärer affektstörung, neurologischen erkrankungen, hartnäckigen und chronischen schmerzen und gehirnverletzungen |
| US9096646B2 (en) | 2008-11-04 | 2015-08-04 | Anchor Therapeutics, Inc. | CXCR4 receptor compounds |
| WO2010065755A1 (en) | 2008-12-04 | 2010-06-10 | Concert Pharmaceuticals, Inc. | Deuterated pyridinones |
| US20110053961A1 (en) | 2009-02-27 | 2011-03-03 | Concert Pharmaceuticals, Inc. | Substituted xanthine derivatives |
| AP2909A (en) | 2009-03-17 | 2014-05-31 | Concert Pharmaceuticals Inc | Pyrazinoisoquinoline Compounds |
| WO2010138889A1 (en) | 2009-05-28 | 2010-12-02 | Concert Pharmaceuticals, Inc. | Peptides for the treatment of hcv infections |
| JP2012531419A (ja) | 2009-06-23 | 2012-12-10 | コンサート ファーマシューティカルズ インコーポレイテッド | Ｇａｂａ−ａ受容体修飾物質としての重水素修飾されたトリアゾロピリダジン誘導体 |
| US20110015154A1 (en) * | 2009-07-20 | 2011-01-20 | Kellermann Gottfried H | Supporting acetylcholine function |
| US8278460B2 (en) | 2009-10-15 | 2012-10-02 | Concert Pharmaceuticals, Inc. | Substituted benzimidazoles |
| US20110098265A1 (en) * | 2009-10-28 | 2011-04-28 | Neuroscience, Inc. | Methods for reducing cravings and impulses associated with addictive and compulsive behaviors |
| WO2011060216A1 (en) | 2009-11-12 | 2011-05-19 | Concert Pharmaceuticals Inc. | Substituted azaindoles |
| EP2536696A1 (de) | 2010-02-18 | 2012-12-26 | Concert Pharmaceuticals Inc. | Pyrimidinderivate |
| EP2566494B1 (de) | 2010-02-26 | 2017-11-29 | Acer Therapeutics, Inc. | Cxcr4-rezeptorverbindungen |
| WO2011109464A1 (en) | 2010-03-02 | 2011-09-09 | Concert Pharmaceuticals Inc. | Deuterated tetrahydronaphthalene derivatives |
| US8575361B2 (en) | 2010-03-02 | 2013-11-05 | Concert Pharmaceuticals Inc. | Tetrahydronaphthalene derivatives |
| PT2579860E (pt) | 2010-06-14 | 2014-05-30 | Ratiopharm Gmbh | Composição farmacêutica que contém ivabradina com libertação modificada |
| WO2012037060A1 (en) | 2010-09-13 | 2012-03-22 | Concert Pharmaceuticals Inc. | Substituted azaindoles |
| EP2455068A1 (de) * | 2010-11-09 | 2012-05-23 | F. Hoffmann-La Roche AG | Pharmazeutische Zusammensetzung zur Behandlung von HCV-Infektionen |
| WO2012065028A2 (en) | 2010-11-11 | 2012-05-18 | Concert Pharmaceuticals Inc. | Substituted tetracyclines |
| WO2012079075A1 (en) | 2010-12-10 | 2012-06-14 | Concert Pharmaceuticals, Inc. | Deuterated phthalimide derivatives |
| US8447329B2 (en) | 2011-02-08 | 2013-05-21 | Longsand Limited | Method for spatially-accurate location of a device using audio-visual information |
| EP2678337A1 (de) | 2011-02-25 | 2014-01-01 | Concert Pharmaceuticals Inc. | 2-amino-naphthyridin-derivate |
| WO2012129381A1 (en) | 2011-03-22 | 2012-09-27 | Concert Pharmaceuticals Inc. | Deuterated preladenant |
| WO2012151361A1 (en) | 2011-05-03 | 2012-11-08 | Concert Pharmaceuticals Inc. | Carbamoylpyridone derivatives |
| US20140128469A1 (en) | 2011-05-10 | 2014-05-08 | Concert Pharmaceuticals Inc. | Deuterated n-butyl bumetanide |
| RS59744B1 (sr) | 2011-05-18 | 2020-02-28 | Vertex Pharmaceuticals Europe Ltd | Deuterisani derivati ivakaftora |
| WO2013013052A1 (en) | 2011-07-19 | 2013-01-24 | Concert Pharmaceuticals, Inc. | Substituted xanthine derivatives |
| FR2985177B1 (fr) * | 2012-01-02 | 2016-04-01 | Oreal | Composition cosmetique solide aqueuse comprenant de l'alkylcellulose, au moins deux huiles non volatiles et au moins deux agents tensioactifs |
| AU2013208109A1 (en) | 2012-01-09 | 2014-08-14 | Anchor Therapeutics, Inc. | APJ receptor compounds |
| WO2013130849A1 (en) | 2012-02-29 | 2013-09-06 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
| CN104364255A (zh) | 2012-04-13 | 2015-02-18 | 康塞特医药品有限公司 | 取代的黄嘌呤衍生物 |
| US9249093B2 (en) | 2012-04-20 | 2016-02-02 | Concert Pharmaceuticals, Inc. | Deuterated rigosertib |
| AU2013274030B2 (en) | 2012-06-15 | 2016-07-07 | Sun Pharmaceutical Industries, Inc. | Deuterated derivatives of ruxolitinib |
| US10017445B2 (en) | 2012-07-12 | 2018-07-10 | Concert Pharmaceuticals, Inc. | Deuterated idebenone |
| EP2885303B1 (de) | 2012-08-17 | 2018-12-26 | CoNCERT Pharmaceuticals, Inc. | Deuteriertes baricitinib |
| WO2014078842A1 (en) | 2012-11-19 | 2014-05-22 | Concert Pharmaceuticals, Inc. | Deuterated cftr potentiators |
| US20150299166A1 (en) | 2012-12-20 | 2015-10-22 | Concert Pharmaceuticals, Inc. | Deuterated alk inhibitors |
| WO2014100733A1 (en) | 2012-12-21 | 2014-06-26 | Mayo Foundation For Medical Education And Research | Methods and materials for treating calcific aortic valve stenosis |
| WO2014110322A2 (en) | 2013-01-11 | 2014-07-17 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
| EA201892726A1 (ru) | 2013-03-15 | 2019-04-30 | Консерт Фармасьютикалс, Инк. | Дейтерированный палбоциклиб |
| EP2968268B1 (de) | 2013-03-15 | 2020-07-29 | Concert Pharmaceuticals Inc. | Inhibitoren des udp-glucose:n-acyl-sphingosin-glucosyltransferase enzyms |
| HU231191B1 (hu) | 2013-04-15 | 2021-08-30 | Szegedi Tudományegyetem | Izotóp tartalmú morfin molekulák |
| WO2015009889A1 (en) | 2013-07-18 | 2015-01-22 | Concert Pharmaceuticals, Inc. | Deuterated intedanib derivatives and their use for the treatment of proliferative disorders |
| WO2015010045A1 (en) | 2013-07-18 | 2015-01-22 | Anchor Therapeutics, Inc. | Apj receptor compounds |
| WO2015031741A1 (en) | 2013-08-30 | 2015-03-05 | Concert Pharmaceuticals, Inc. | Deuterated derivatives of a thienotriazolodiazapine bromodomain-containing protein inhibitor |
| CN106459056A (zh) | 2014-02-10 | 2017-02-22 | 康塞特医药品公司 | 经取代的三唑苯二氮卓 |
| US20170216296A1 (en) | 2014-04-18 | 2017-08-03 | Concert Pharmaceuticals, Inc. | Methods of treating hyperglycemia |
| WO2015179772A1 (en) | 2014-05-23 | 2015-11-26 | Concert Pharmaceuticals, Inc. | Deuterated phenylquinazolinone and phenylisoquinolinone compounds |
| BR112016028119A2 (pt) | 2014-06-06 | 2017-08-22 | Res Triangle Inst | Agonistas receptores de apelina (apj) e usos dos mesmos |
| WO2016022955A1 (en) | 2014-08-07 | 2016-02-11 | Mayo Foundation For Medical Education And Research | Compounds and methods for treating cancer |
| WO2016061488A1 (en) | 2014-10-17 | 2016-04-21 | Concert Pharmaceuticals, Inc. | Amine reuptake inhibitors |
| WO2016073545A1 (en) | 2014-11-06 | 2016-05-12 | Concert Pharmaceuticals, Inc. | Phenyloxadiazole benzoic acids |
| WO2016089814A1 (en) | 2014-12-02 | 2016-06-09 | Concert Pharmaceuticals, Inc. | Deuterated analogues of daclatasvir |
| US10301281B2 (en) | 2014-12-11 | 2019-05-28 | Merck Sharp & Dohme Corp. | Crystal forms of a CCR5 antagonist |
| CN105769809A (zh) * | 2014-12-23 | 2016-07-20 | 上海星泰医药科技有限公司 | 提高生物利用度的雷尼司他及其制备方法 |
| WO2016105547A1 (en) | 2014-12-24 | 2016-06-30 | Concert Pharmaceuticals, Inc. | Deuterated dasabuvir |
| WO2016109795A1 (en) | 2014-12-31 | 2016-07-07 | Concert Pharmaceuticals, Inc. | Deuterated funapide and difluorofunapide |
| WO2016144830A1 (en) | 2015-03-06 | 2016-09-15 | Concert Pharmaceuticals, Inc. | Deuterated emricasan |
| CA2981495C (en) | 2015-03-31 | 2023-09-26 | Vertex Pharmaceuticals (Europe) Limited | Deuterated vx-661 |
| WO2016176335A1 (en) | 2015-04-27 | 2016-11-03 | Concert Pharmaceuticals, Inc. | Deuterated otx-015 |
| US20180243289A1 (en) | 2015-07-30 | 2018-08-30 | Concert Pharmaceuticals, Inc. | Deuterated morphinan compounds for treating agitation |
| WO2017020005A1 (en) | 2015-07-30 | 2017-02-02 | Concert Pharmaceuticals, Inc. | Morphinan compounds for use in treating agitation |
| MX2018003331A (es) | 2015-09-21 | 2018-08-16 | Vertex Pharmaceuticals Europe Ltd | Administracion de potenciadores de regulador de la conductancia transmembrana de fibrosis quistica (cftr) deuterados. |
| US11267777B2 (en) | 2015-11-19 | 2022-03-08 | Concert Pharmaceuticals, Inc. | Deuterated EPI-743 |
| EP3386976A1 (de) | 2015-12-09 | 2018-10-17 | Research Triangle Institute, International | Verbesserte apelinrezeptor (apj)-agonisten und verwendungen davon |
| WO2017147003A1 (en) | 2016-02-26 | 2017-08-31 | Novobiotic Pharmaceuticals, Llc | Novel macrocyclic antibiotics and uses thereof |
| KR20190003711A (ko) | 2016-05-04 | 2019-01-09 | 콘서트 파마슈티컬즈, 인크. | 중수소화된 jak 저해제를 이용한 탈모 장애의 치료 |
| JP7061079B2 (ja) | 2016-07-04 | 2022-04-27 | アヴェニール ファーマシューティカルズ， インコーポレイテッド | 重水素化デキストロメトルファンの合成方法 |
| US11596605B2 (en) | 2016-08-01 | 2023-03-07 | The Brigham And Women's Hospital, Inc. | Particles for delivery of proteins and peptides |
| CA3036382A1 (en) | 2016-12-21 | 2018-06-28 | Research Triangle Institute | Diaryl purine derivatives with improved bioavailability |
| WO2018160717A1 (en) | 2017-02-28 | 2018-09-07 | Mayo Foundation For Medical Education And Research | Compounds and methods for treating cancer |
| US11278025B2 (en) | 2017-05-17 | 2022-03-22 | The General Hospital Corporation | Antibiotic compounds |
| BR112019024177A2 (pt) | 2017-05-19 | 2020-06-02 | Superb Wisdom Limited | Derivados de resiquimode |
| JP7518765B2 (ja) | 2017-11-22 | 2024-07-18 | コンサート ファーマシューティカルズ インコーポレイテッド | Ｄ－セリンの重水素化類似体およびその使用 |
| US11243207B2 (en) | 2018-03-29 | 2022-02-08 | Mayo Foundation For Medical Education And Research | Assessing and treating cancer |
| WO2021236139A1 (en) | 2020-05-21 | 2021-11-25 | Concert Pharmaceuticals, Inc. | Novel deuterated jak inhibitor and uses thereof |
| MX2023005027A (es) | 2020-10-28 | 2023-07-31 | Sun Pharmaceutical Ind Inc | Regimenes para el tratamiento de los trastornos de la perdida de cabello con inhibidores de jak deuterados. |
| AU2022328272A1 (en) | 2021-08-11 | 2024-02-22 | Sun Pharmaceutical Industries, Inc. | Treatment of hair loss disorders with deuterated jak inhibitors |
| JP2024532765A (ja) | 2021-08-12 | 2024-09-10 | サン ファーマシューティカル インダストリーズ，インコーポレイテッド | Ｊａｋ阻害剤のプロドラッグを用いたｊａｋ阻害応答性障害の治療 |
| WO2023215520A1 (en) | 2022-05-04 | 2023-11-09 | Sun Pharmaceutical Industries, Inc. | Dosage regimens for treatment with deuterated jak inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5281420A (en) | 1992-05-19 | 1994-01-25 | The Procter & Gamble Company | Solid dispersion compositions of tebufelone |
| IE80467B1 (en) * | 1995-07-03 | 1998-07-29 | Elan Corp Plc | Controlled release formulations for poorly soluble drugs |
| US5834472A (en) | 1996-05-24 | 1998-11-10 | Schering Corporation | Antifungal composition with enhanced bioavailability |
| US6232333B1 (en) * | 1996-11-21 | 2001-05-15 | Abbott Laboratories | Pharmaceutical composition |
| US6045829A (en) * | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
| US6001851A (en) | 1997-03-13 | 1999-12-14 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
| JP4083818B2 (ja) * | 1997-06-06 | 2008-04-30 | ディポメド，インコーポレイティド | 高度可溶性薬物の制御された放出のための胃滞留性の経口薬物投与形 |
| WO1998057648A1 (en) * | 1997-06-16 | 1998-12-23 | Vertex Pharmaceuticals Incorporated | Methods of increasing the bioavailability of stable crystal polymorphs of a compound |
| JP2002522354A (ja) * | 1997-09-19 | 2002-07-23 | シャイア ラボラトリーズ，インコーポレイテッド | 固溶体ビードレット |
| JP4815085B2 (ja) * | 1999-11-12 | 2011-11-16 | アボット・ラボラトリーズ | 固体分散体医薬製剤 |
| US6499984B1 (en) * | 2000-05-22 | 2002-12-31 | Warner-Lambert Company | Continuous production of pharmaceutical granulation |
-
2002
- 2002-04-29 JP JP2002586967A patent/JP4101661B2/ja not_active Expired - Fee Related
- 2002-04-29 SK SK1457-2003A patent/SK14572003A3/sk unknown
- 2002-04-29 WO PCT/EP2002/004711 patent/WO2002089835A2/en active IP Right Grant
- 2002-04-29 PT PT02748680T patent/PT1390063E/pt unknown
- 2002-04-29 AT AT02748680T patent/ATE282428T1/de active
- 2002-04-29 HU HU0401238A patent/HU229938B1/hu not_active IP Right Cessation
- 2002-04-29 EP EP02748680A patent/EP1390063B1/de not_active Expired - Lifetime
- 2002-04-29 KR KR1020037014234A patent/KR100554816B1/ko not_active IP Right Cessation
- 2002-04-29 EA EA200301166A patent/EA006627B1/ru not_active IP Right Cessation
- 2002-04-29 UA UA20031210981A patent/UA76463C2/uk unknown
- 2002-04-29 DE DE60201988T patent/DE60201988T2/de not_active Expired - Lifetime
- 2002-04-29 MX MXPA03009971A patent/MXPA03009971A/es active IP Right Grant
- 2002-04-29 RS YU83503A patent/RS83503A/sr unknown
- 2002-04-29 CA CA002444116A patent/CA2444116C/en not_active Expired - Fee Related
- 2002-04-29 CZ CZ20033211A patent/CZ20033211A3/cs unknown
- 2002-04-29 GE GE5295A patent/GEP20053466B/en unknown
- 2002-04-29 CN CNB028092953A patent/CN1255185C/zh not_active Expired - Fee Related
- 2002-04-29 IL IL15830602A patent/IL158306A0/xx unknown
- 2002-04-29 ES ES02748680T patent/ES2231717T3/es not_active Expired - Lifetime
- 2002-04-29 BR BR0209325-1A patent/BR0209325A/pt not_active Application Discontinuation
- 2002-04-29 PL PL02366998A patent/PL366998A1/xx unknown
- 2002-04-29 NZ NZ528689A patent/NZ528689A/en unknown
- 2002-04-30 AR ARP020101580A patent/AR034320A1/es not_active Application Discontinuation
- 2002-04-30 PA PA20028544501A patent/PA8544501A1/es unknown
- 2002-04-30 PE PE2002000369A patent/PE20021159A1/es not_active Application Discontinuation
- 2002-04-30 TW TW091108967A patent/TWI234461B/zh not_active IP Right Cessation
- 2002-04-30 MY MYPI20021591A patent/MY128509A/en unknown
- 2002-05-01 JO JO200237A patent/JO2401B1/en active
- 2002-05-02 GT GT200200079A patent/GT200200079A/es unknown
- 2002-05-02 US US10/138,071 patent/US7014866B2/en not_active Expired - Fee Related
-
2003
- 2003-10-08 IL IL158306A patent/IL158306A/en not_active IP Right Cessation
- 2003-10-20 NO NO20034689A patent/NO20034689D0/no not_active Application Discontinuation
- 2003-10-28 HR HR20030873A patent/HRP20030873B1/xx not_active IP Right Cessation
- 2003-10-30 IS IS7010A patent/IS7010A/is unknown
- 2003-10-31 EC EC2003004827A patent/ECSP034827A/es unknown
- 2003-11-03 MA MA27379A patent/MA27018A1/fr unknown
- 2003-11-03 BG BG108311A patent/BG108311A/bg unknown
-
2005
- 2005-04-11 HK HK05103024A patent/HK1070285A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA76463C2 (en) | Pharmaceutical dosage form of amorphous nelfinavir mesylate | |
| US6291462B1 (en) | Oral medicinal preparations with reproducible release of the active ingredient gatifloxacin or its pharmaceutically suitable salts or hydrates | |
| CA2435714C (en) | Fenofibrate tablets | |
| KR20150015500A (ko) | 엔테카비어의 약제학적 조성물 및 제조 방법 | |
| JPH0717866A (ja) | 医薬組成物 | |
| JP2010280707A (ja) | メシル酸サキナビル経口投与剤型 | |
| JP2010534222A (ja) | ダルナビルを含んでなる抗ｈｉｖ錠剤製剤 | |
| JP4572296B2 (ja) | ピモベンダン経口投与製剤 | |
| JPH1121236A (ja) | ロキソプロフェン・ナトリウム固形製剤 | |
| JPH09143065A (ja) | イブプロフェン含有錠剤及びその製造法 | |
| JP3837062B2 (ja) | 難溶性薬物を含有する複合粒固形製剤 | |
| WO2020122244A1 (ja) | 錠剤及びその製造方法 | |
| AU2002319154B2 (en) | Pharmaceutical dosage form of amorphous nelfinavir mesylate | |
| JP5563841B2 (ja) | 薬物の不快な味をマスキングした経口医薬組成物 | |
| JP4591742B2 (ja) | ジオクチルソジウムスルホサクシネート配合製剤およびその製造方法 | |
| AU2002319154A1 (en) | Pharmaceutical dosage form of amorphous nelfinavir mesylate | |
| JPS59106424A (ja) | 易吸収性キノリンカルボン酸誘導体組成物およびその製剤 | |
| CA3234371A1 (en) | An orodispersible pharmaceutical dosage form of edoxaban | |
| JP2012197266A (ja) | セチリジン塩酸塩を含有する医薬組成物 | |
| JP2005255595A (ja) | ジオクチルソジウムスルホサクシネート配合錠剤 | |
| JPH0867631A (ja) | ビタミンｅ含有内服剤用固形組成物 | |
| JP2005015363A (ja) | 小型化クラリスロマイシン錠剤 | |
| JP2005206519A (ja) | 用時溶解型速溶性固形製剤 |